TGen-Virginia G. Piper Cancer Center pancreatic cancer clinical trial results released

SU2C-funded study is the first to evaluate treatment based on molecular profiling of advanced pancreatic cancer

2012-04-04

(Press-News.org) CHICAGO --The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

The findings were announced during the American Association for Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago.

"The most important finding is that this approach is feasible and we are encouraged by preliminary evidence that this approach may benefit some patients," said Dr. Ramesh K. Ramanathan, Medical Director of the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen.

The completed phase II clinical trial: Therapy Selected by Tumor Molecular Profiling in Patients with Previously Treated Metastatic Pancreatic Cancer, is part of a Stand Up To Cancer (SU2C) Pancreatic Cancer Dream Team consortium created in 2009.

Dr. Ramanathan said this is the first clinical study of pancreatic cancer in which biopsies were done of the tumors and treatments were based on the molecular profiling of pancreatic cancer tumors.

The study showed that biopsies could be safely conducted, and that multiple drug targets could be identified by IHC and DNA sequencing (Caris Target Now®), CGH and microarray.

"Survival analysis is premature, but we believe some patients have had benefit," Dr. Ramanathan said.

Forty-nine subjects were accrued between August 2010 and January 2012. Fourteen patients did not start protocol therapy either due to insufficient tumor on biopsy or due to worsening cancer related symptoms after biopsy. There were 35 evaluable patients.

In most patients — all of whom had prior chemotherapy — molecular profiling at Caris resulted in two or more IHC targets for therapy and a non-cross resistant regimen could be implemented.

The most common IHC targets were topoisomerase 1 or 2 and Thymidylatesynthase. Only commercially available agents were prescribed. Treatment recommendations were based primarily on IHC markers. Common regimens/ agents recommended were FOLFIRI, FOLFOX, irinotecan and doxorubicin.

Study has completed accrual. One patient treated with FOLFIRI is a one-year survivor.

Genomic (CGH and microarray) assays and pathway analysis are ongoing to understand response and molecular factors identified in the cancer cells..

The study's abstract will be presented at an AACR Late-Breaking Poster Session from 8 a.m.-12 p.m. today at Chicago's McCormick Place convention center.

###Collaborators on the study included: Johns Hopkins University School of Medicine; Cancer Research And Biostatistics, Seattle; and the Spanish National Cancer Center, Madrid. The study used Caris Target Now® for molecular profiling of markers by IHC and KRAS mutational analysis by direct sequencing.

About the Virginia G. Piper Cancer Center at Scottsdale Healthcare The Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Ariz. offers comprehensive cancer care and research through Phase I clinical trials, diagnosis, treatment, prevention and support services in collaboration with leading scientific researchers and community oncologists. Scottsdale Healthcare is the nonprofit parent organization of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute, Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital. For more information, visit www.shc.org.

Press Contact: Jamie Houston
Public Relations Coordinator
Virginia G. Piper Cancer Center
480-323-1387
jhouston@shc.org

About TGen The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Press Contact: Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org

ELSE PRESS RELEASES FROM THIS DATE:

Chemo may get boost from cholesterol-related drug

2012-04-04

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs. Besides their deadly consequences, pancreatic cancer and heart disease share a connection with genetic pathways that control cholesterol and a cell signaling system known as the Hedgehog pathway. (The name refers to the shape of its mutated protein in fruit flies, ...

How social contact with sick ants protects their nestmates

2012-04-04

In a research article published April 3 in the online, open-access journal PLoS Biology, Prof. Sylvia Cremer and colleagues at the Institute of Science and Technology, Austria show how micro-infections promote social vaccination in ant societies. Like crowded megacities, ant colonies face a high risk of disease outbreaks. These are kept in check by the ants' social immune system—a set of collective hygienic behaviours and adaptive changes in interaction frequencies that acts in conjunction with the physiological, innate immune system of colony members. Prof. Cremer and ...

Anago Cleaning Systems Hosts Annual Master Franchise Conference in Orlando

2012-04-04

Top executives at Anago Cleaning Systems hosted its 2012 annual conference for their Master Franchisees in an effort to celebrate major growth and successes in 2011, and prepare for aggressive expansion and improvement throughout each territory and the nation. New and existing Master Franchisees alike attended the two-day show that was held on March 5-6, 2012 in Orlando, Florida. The convention kicked off with opening remarks from Anago Cleaning Systems Founder, David Povlitz. Mr. Povlitz reiterated that the vision, mission, and values of the company he founded in ...

Researchers use a game to change how scientists study outbreaks

2012-04-04

An international team of scientists has created an innovative tool for teaching the fundamentals of epidemiology—the science of how infectious diseases move through a population. The team teaches a workshop annually in South Africa that helps epidemiologists improve the mathematical models they use to study outbreaks of diseases like cholera, AIDS and malaria. Led by Steve Bellan from the University of California at Berkeley, the team created a new game as a teaching aid for the workshop. The exercise, which has proven extremely effective in demonstrating concepts in ...

How do cancers become resistant to chemotherapy?

2012-04-04

Genetic mutations in cancer cells can lead to resistance to treatment, thereby potentially resulting in relapse. However, a new article, published April 3 in the magazine section of the online, open-access journal PLoS Biology, suggests that the converse may also happen. Steven Frank from the University of California, Irvine, and Marsha Rosner from the University of Chicago, propose that it may often be the case that a few cells become resistant before any genetic change, and then later acquire the genes to stabilize that resistance. Why does it matter whether resistance ...

First New England SalesPad Software User Group Hosted by Connecticut Dynamics GP Partner CAL Business Solutions

2012-04-04

CAL Business Solutions, a Connecticut based Microsoft Dynamics GP partner, today announced that it will host the first ever New England SalesPad user group workshop. Companies using Microsoft Dynamics GP with SalesPad, an add on product for the distribution industry, will have the opportunity to come together to see new features, share ideas, network with their peers and provide input on future product developments. The user group will be held at the Crowne Plaza hotel in Cromwell, Connecticut from 8:00-11:30am on Monday May 7th. Topics on the agenda include advanced ...

New hormone for lowering blood sugar

2012-04-04

New evidence points to a hormone that leaves muscles gobbling up sugar as if they can't get enough. That factor, which can be coaxed out of fat stem cells, could lead to a new treatment to lower blood sugar and improve metabolism, according to a report in the April issue of Cell Metabolism, a Cell Press publication. This new fat-derived hormone would appear to be a useful alternative or add-on to insulin; it can do essentially the same job, sending glucose out of the bloodstream and into muscle. "It's like you've opened the door and now the glucose can come in," said ...

Strong and consistent evidence supports low-energy-density diets for weight loss

2012-04-04

Philadelphia, PA, April 3, 2012 – A new report published online today in the Journal of the Academy of Nutrition and Dietetics systematically reviews and updates the evidence underlying the recommendation in the Dietary Guidelines for Americans 2010 to consume a diet low in energy density (ED). The report addresses the growing body of evidence linking ED, or the number of calories in a given amount of food, and body weight in adults as well as children and adolescents. The systematic review concluded that there is strong and consistent evidence in adults showing that consuming ...

How a cancer drug leads to diabetes

2012-04-04

The drug known as rapamycin is widely used by cancer and transplant patients, and there are hints that it might even help us put off old age and live longer. But, it also comes with a downside: rapamycin leads to diabetes in as many as 15 percent of the people who take it. Now, researchers reporting in the April Cell Metabolism, a Cell Press publication, have figured out why that is. The drug turns the insulin signal off in muscle, to prevent muscle cells from taking blood sugar in. "This is a drug that is pretty well known for its benefits," said Pere Puigserver ...

Researchers discover a DNA marker that indicates if ovarian cancer treatment will be successful

2012-04-04

CHICAGO, IL – Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered that blood can help determine the best treatment plan for patients with ovarian cancer. More specifically, a genetic marker embedded in deoxyribonucleic acid (DNA), called microRNA, indicates if a patient with ovarian cancer has a benign or cancerous tumor, and that she will benefit from chemotherapy after surgery on the tumor. This data will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held ...

TGen-Virginia G. Piper Cancer Center pancreatic cancer clinical trial results released

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: